•  
  •  
 

References

1. Clayton PA, McDonald SP, Snyder JJ, Salkowski N, Chadban SJ. External validation of the estimated posttransplant survival score for allocation of deceased donor kidneys in the United States. Am J Transplant. 2014;14(8):1922– 1926.

2. Lentine KL, Smith JM, Miller JM, et al. OPTN/SRTR 2021 Annual data report: Kidney. Am J Transplant. 2023;23(2 Suppl 1):S21–S120.

3. Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet. 2011;378(9800):1428– 1437.

4. Tantisattamo E, Leventhal JR, Mathew JM, Gallon L. Chimerism and tolerance: past, present and future strategies to prolong renal allograft survival. Curr Opin Nephrol Hypertens. 2021;30(1):63–74.

5. Kaufman DB, Akkina SK, Stegall MD, et al. Induction of immune tolerance in living related human leukocyte antigenmatched kidney transplantation: A phase 3 randomized clinical trial. Am J Transplant. 2025;25(7):1461–1470.

6. Leventhal JR, Krieger NR, Tambur AR, Schneider K, Olsen J, Ildstad ST. Establishment of durable chimerism with minimal GvHD in highly mismatched recipients receiving an investigational facilitated Allo-HSCT. Blood. 2021;138:911.

7. Stark H, Ho QY, Cross A, et al. Meeting report: The sixth international Sam Strober workshop on clinical immune tolerance. Transplantation. 2025;109(4):569–579.

8. Roemhild A, Otto NM, Moll G, et al. Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial. BMJ. 2020;371:m3734.

9. Sawitzki B, Harden PN, Reinke P, et al. Regulatory cell therapy in kidney transplantation (the ONE study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. Lancet. 2020;395(10237):1627–1639.

10. Moreau A, Kervella D, Bouchet-Delbos L, et al. A phase I/IIa study of autologous tolerogenic dendritic cells immunotherapy in kidney transplant recipients. Kidney Int. 2023;103(3):627–637.

11. Amini L, Wagner DL, Rossler U, et al. CRISPR-Cas9-edited tacrolimus-resistant antiviral T cells for advanced adoptive immunotherapy in transplant recipients. Mol Ther. 2021;29(1):32–46.

Download

Share

COinS